Tokyo, Japan

Akihiko Kanno


Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 1985-1988

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Akihiko Kanno: Innovator in Pharmaceutical Chemistry

Introduction

Akihiko Kanno, based in Tokyo, Japan, is a distinguished inventor known for his contributions to the field of pharmaceutical chemistry. With a total of seven patents to his name, Kanno has made notable advancements in the development of cephalosporin derivatives, which are vital in the fight against bacterial infections.

Latest Patents

Among his latest innovations, Kanno has developed N-(substituted)-[7-(2-cyanoacetamido)cephalosporanic]amide derivatives. These compounds are characterized by their complex formulas that include various functional groups, such as 4-pyridylthiomethyl and alpha-aminobenzyl groups. His research also covers the creation of cephalosporin derivatives aimed at enhancing antibiotic efficacy, showcasing a novel approach to producing pharmaceutical compositions and antibacterial agents.

Career Highlights

Kanno is employed at Kureha Kagaku Kogyo Kabushiki Kaisha, a company renowned for its advancements in the chemical manufacturing sector. His work in this organization is marked by a dedication to innovative solutions, leading to the successful patenting of several significant pharmaceutical compounds.

Collaborations

Throughout his career, Akihiko Kanno has collaborated with esteemed colleagues, including Shigeaki Muto and Takao Ando. Together, they have worked towards pushing the boundaries of pharmaceutical science, constantly striving to create better therapeutic options for patients.

Conclusion

As an accomplished inventor, Akihiko Kanno exemplifies the impact of innovation in the pharmaceutical industry. Through his patents and collaborative efforts, he continues to contribute significantly to advancing medical treatments that improve health outcomes worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…